

Sponsorship Agreement: Colitis-Crohn Foreningen

This Agreement (the “**Agreement**”) is entered into by and between:

[A]	Eli Lilly Danmark A/S, reg.no 51619811, Lyskær 3E, 2730 Herlev, Denmark (“ Lilly ”)
------------	--

[B]	Colitis-Crohn Foreningen, Kongensgade 66-68, 2.TH, 5000 Odense C, Denmark (the “ PAG ”)
------------	--

each a “**Party**”, and jointly the “**Parties**”.

RECITALS

Lilly is an affiliate of Eli Lilly and Company, a global research-based pharmaceutical corporation that develops, manufactures and sells pharmaceutical products within, *inter alia*, the medical field of gastroenterology.

PAG is a non-political, non-profit patient advocacy group with the purposes of supporting patients with colitis and crohn’s and increasing awareness of colitis and crohn’s and their effects among the general public, legislators and policymakers.

PAG intends to arrange the Meeting (as defined below) within the field of colitis and crohn’s. Lilly intends to contribute with economic support in the form of sponsorship for the performance of the meeting, in return for certain counter performances as further described below.

Therefore, the Parties wish to enter into this Agreement as follows.

AGREEMENT

1. DESCRIPTION AND PURPOSE OF MEETING

- 1.1. During 2025, PAG is arranging to update CCF’s 10 brochures as further described in *Appendix I* (the “**Meeting**”).
- 1.2. The purpose of Lilly’s sponsorship is to support the update of brochures project (the “**Purpose**”).

2. INDEPENDENCE

- 2.1. The Parties acknowledge that this Agreement is solely to provide the Sponsorship Fee for the Purpose as described above.

- 2.2. The Parties acknowledge that the Meeting is the sole idea of PAG and will be arranged by PAG independently. Lilly will not have any influence as to the Meeting's agenda, contents, or in general as to how the Meeting is arranged. Lilly does however reserve the right to carry out a check of all output of content associated with the sponsorship to ensure that there are no factual inaccuracies surrounding Lilly.
- 2.3. The Parties acknowledge that PAG and/or any related HCPs under no circumstances has any obligation to buy, use or recommend any Lilly product in return for the Sponsorship Fee under this Agreement.
- 2.4. PAG confirms that more than one pharmaceutical company has been offered an equal opportunity to sponsor the Meeting

3. SPONSORSHIP FEE AND FINANCIAL CONSIDERATIONS

- 3.1. Lilly agrees to be a sponsor of the Meeting and undertakes to contribute with an amount of in aggregate 44200 DKK excl VAT (the "**Sponsorship Fee**").
- 3.2. Lilly's Sponsorship Fee is based on the agenda and budget for the Meeting as attached in *Appendix 1*. The budget shall reflect all PAG's costs related to the Meeting.
- 3.3. Lilly will contribute with the Sponsorship Fee by way of paying an invoice where the basis for the invoiced amount shall be specified. Payment shall be made by Lilly 60 days from the receipt of a valid invoice. Any invoice shall be sent to milligan_lene_thorsgaard@lilly.com.

4. USE OF THE SPONSORSHIP FEE

- 4.1. PAG may only use the Sponsorship Fee to implement the professional parts of the Meeting in accordance with applicable industry code, such as costs of the premises, speakers, materials, moderate meals in connection with the Meeting. PAG is not allowed to use the Sponsorship Fee to cover other kind of costs, whether it may be for the Meeting or for other purposes. PAG is not allowed to use the Sponsorship Fee to finance PAG's ordinary business operations.
- 4.2. Furthermore, the Parties agree that Lilly has granted the sponsorship on the condition that it is used solely in accordance with the Purpose set out in Section 1 above. Should any information set out in Section 1 and/or Appendix 1, such as venue, timing, content or purpose, change in anyway after signature of this Agreement, PAG shall promptly contact Lilly and Lilly shall have the right to request return of all or a portion of the Sponsorship Fee.

5. THE RIGHTS GRANTED IN RETURN FOR LILLY'S SPONSORSHIP

NA

6. COMPLIANCE ETC.

- 6.1. In connection with this Agreement and the Meeting, the Parties shall comply with all applicable laws, regulations and industry codes, including ENLI / LIF and the General Data Protection Regulation ((EU) 2016/079 "GDPR" and any related national legislation (as amended from time to time).

- 6.2. The Meeting and any other interactions between the Parties in connection with this Agreement shall be entirely product-neutral and shall not include any promotion of medicinal products;
- 6.3. The Parties acknowledge that PAG under no circumstances has any obligation to buy, use or recommend any Lilly product in return for the Sponsorship Fee under this Agreement.

7. ANTI-CORRUPTION

- 7.1. **Definitions.** "Government Official" means: (i) any officer or employee of: (a) a government, or any department or agency thereof; (b) a government-owned or controlled company, institution, or other entity, including a government-owned hospital or university; or (c) a public international organization (such as the United Nations, the International Monetary Fund, the International Committee of the Red Cross, and the World Health Organization), or any department or agency thereof; (ii) any political party or party official or candidate for public or political party office; and (iii) any person acting in an official capacity on behalf of any of the foregoing.
- 7.2. **Compliance with Anti-Corruption Laws.** In connection with this Agreement, PAG will comply with all applicable local, national, and international laws, regulations, and industry codes dealing with government procurement, conflicts of interest, corruption or bribery, including, if applicable, the U.S. Foreign Corrupt Practices Act of 1977 ("**FCPA**"), as amended, and any laws enacted to implement the Organisation of Economic Cooperation and Development ("**OECD**") Convention on Combating Bribery of Foreign Officials in International Business Transactions.
- 7.3. **Prohibited Conduct.** In connection with this Agreement, PAG has not made, offered, given, promised to give, or authorized, and will not make, offer, give, promise to give, or authorize, any bribe, kickback, payment or transfer of anything of value, directly or indirectly, to any person or to any Government Official for the purpose of: (i) improperly influencing any act or decision of the person or Government Official; (ii) inducing the person or Government Official to do or omit to do an act in violation of a lawful or otherwise required duty; (iii) securing any improper advantage; or (iv) inducing the person or Government Official to improperly influence the act or decision of any organization, including any government or government instrumentality, to assist PAG or Lilly in obtaining or retaining business.
- 7.4. **Requests for Information.** PAG will make all reasonable efforts to comply with requests for disclosure of information, including answering questionnaires and narrowly tailored audit inquiries, to enable Lilly to ensure compliance with all applicable laws, including anti-corruption laws, industry codes, and this Agreement.
- 7.5. **Fair Market Value.** PAG acknowledges and agrees that all compensation that Lilly will pay, including the Sponsorship Fee, has been determined through good faith, arms-length negotiation and constitutes the fair market value.
- 7.6. **Notice of Inspections.** PAG shall provide Lilly with immediate notice of any governmental or regulatory review, audit, or inspection of its facility, processes, or products that might relate to the subject matter of this Agreement. PAG shall provide Lilly with the results of any such review, audit or inspection. Lilly shall be given the opportunity to provide assistance to PAG in responding to any such review, audit, or inspection.

- 7.7. **Accuracy of Books and Records / Cooperation with Audit Activities.** PAG agrees that it will maintain accurate and complete records having to do with this Agreement during the term of this Agreement and for a period of five (5) years thereafter. PAG further agrees that it will maintain adequate internal controls. PAG will make relevant documents available for review by Lilly, or an independent party nominated by Lilly, to show compliance with this requirement at Lilly's request.
- 7.8. **Cooperation in Investigation.** PAG agrees to cooperate in good faith to investigate the extent of any potential violations of law or industry codes in connection with this Agreement.
- 7.9. **Disclosure Rights.** At any time, and without notice to PAG, Lilly may disclose information relating to a possible violation of law, or the existence of the terms of this Agreement, including the compensation provisions, to a government agency and to anyone that Lilly determines to have a legitimate need to know.
- 7.10. PAG agrees that breach of this section of the Agreement shall be considered a material breach of the Agreement and that Lilly may immediately seek all remedies available under law, including termination of this Agreement, if it believes, in good faith, that PAG has breached a provision of this section of the Agreement. If this Agreement is terminated pursuant to this provision, Lilly may seek reimbursement or refund of any fees (including the Sponsorship Fee), other compensation or expense reimbursement that Lilly has paid, and no further amounts shall be due pursuant to this Agreement.

8. TRADE SANCTIONS

- 8.1. PAG agrees to comply with all applicable trade sanctions and export control laws and regulations, including where applicable the U.S. trade sanctions administered by the U.S. Treasury Department's Office of Foreign Assets Control (31 C.F.R. Part 501 et seq.), the U.S. Export Administration Regulations (15 C.F.R. Part 734 et seq.), and European Union trade sanctions and export laws (including without limitation Council Regulation (EC) No. 428/2009 (as amended)).
- 8.2. PAG represents and warrants that neither PAG, its directors, executive officers, agents, shareholders nor any person having a controlling interest in PAG are (i) a person targeted by trade or financial sanctions under the laws and regulations of the United Nations, the United States, the European Union and its Member States, the United Kingdom or any other jurisdiction that is applicable to the rights under this Agreement, including but not limited to persons designated on the U.S. Department of the Treasury, Office of Foreign Assets Control's List of Specially Designated Nationals and Other Blocked Persons and Consolidated Sanctions List, the U.S. State Department's Non-proliferation Sanctions Lists, the UN Financial Sanctions Lists, the EU's Consolidated List of Persons, Groups and Entities Subject to EU Financial Sanctions, and the UK HM Treasury Consolidated Lists of Financial Sanctions Targets; (ii) incorporated or headquartered in, or organized under the laws of, a territory subject to comprehensive U.S. sanctions (each, a "Sanctioned Territory") (currently, Cuba, Iran, Crimea, North Korea, Syria and Venezuela but subject to change at any time) or (iii) directly or indirectly owned or controlled by such persons (together "Restricted Person"). PAG further represents and warrants that PAG shall notify Lilly in writing immediately if PAG or any of its directors, executive officers, agents, shareholders or any person having a controlling interest in PAG becomes a Restricted Person or if PAG becomes directly or indirectly owned or controlled by one or more Restricted Persons.

9. TERM AND TERMINATION

- 9.1. This Agreement shall enter into force on the last date of signature by the Parties and remain in force until completion of the Meeting and upon final settlement of the Sponsorship Fee, after which it shall expire without further notice.
- 9.2. For the avoidance of doubt, Lilly may be obliged, per local code requirements, to submit details about the sponsorship, including a copy of the agreement, to ENLI prior to a fully signed agreement by the Parties. The Parties acknowledge that such prior submission shall not constitute a legally binding agreement between the Parties or otherwise a promise to provide financial contribution. Reference is made to Section 9.1 requiring a fully signed agreement by the Parties in order for the Agreement to enter into force.
- 9.3. This Agreement may be terminated by either Party upon thirty (30) days written notice to the other Party at any time.
- 9.4. Lilly may terminate this Agreement immediately upon written notice if Lilly reasonably believes that PAG has materially breached this Agreement, which includes e.g. actions that are contrary to applicable legislation, regulations or industry codes.

10. REPORTING

In accordance with applicable regulations and industry code, the financial outcome of the Meeting shall upon Lilly's request be promptly reported by PAG to Lilly after the Meeting is completed. Should the financial outcome show that the Sponsorship Fee having been contributed to the Meeting by sponsors have generated a surplus to PAG, a refund shall, as a general rule, be made to the companies that have participated as sponsors, including Lilly.

11. CANCELLATIONS OR CHANGES TO MEETING

- 11.1. To the extent the Meeting, for any reason, cannot take place or be implemented, no Sponsorship Fee will be paid by Lilly. If parts of the Meeting, for any reason, cannot take place, a pro rata reduction of the Sponsorship Fee shall be made.
- 11.2. To the extent the Sponsorship Fee have already been paid to PAG and it turns out the Meeting wholly or partly cannot take place, PAG must promptly refund the funds received, wholly or partly as applicable, to Lilly.

12. TRANSPARENCY

- 12.1. PAG shall, on their website, or other suitable place, well in advance before the Meeting publicly announce that Lilly (and other possible sponsors) has contributed with financial sponsoring to the Meeting so that this is clear to all Meeting participants and also to third parties.
- 12.2. Lilly shall comply with all applicable transparency requirements for pharmaceutical companies in Denmark including the requirements as set out in the ENLI guidance, to the extent these provisions are applicable. PAG acknowledges that Lilly may be obligated to report any value transfers to PAG under this Agreement to the LIF / EFPIA, in accordance with the applicable rules for reporting transfers of value to healthcare professionals and healthcare organizations.

PAG consents to such reporting by Lilly, to the extent required under the applicable rules and regulations.

13. INTELLECTUAL PROPERTY

- 13.1. All rights in the Lilly logo or trade mark or any other trade mark or logo held by Eli Lilly and Company or its affiliates (the “**Lilly Marks**”), including any goodwill associated with them, shall be the sole and exclusive property of Eli Lilly and Company (or its affiliates) and PAG shall not acquire any rights in the Lilly Marks. The Lilly Marks cannot be used without prior written consent of Eli Lilly and Company.
- 13.2. Lilly shall be entitled to use PAG’s name and logotype in any communications about the Meeting in relation to third parties for the purpose of highlighting its sponsorship of the Meeting.

14. CONFIDENTIALITY

The Parties agree that each shall treat as confidential all information, including without limitation information about a Party’s business and operations as well as the terms of this Agreement. All confidential information provided by a Party hereto shall be used by the other Party solely for the purposes of completing the obligations pursuant to this Agreement and shall not be disclosed to any third party without the prior consent of such providing party. The foregoing shall not be applicable to any information that is publicly available when provided or which thereafter becomes publicly available other than in breach of this Agreement or which is required to be disclosed by applicable laws, regulations and industry codes or by a court order.

15. PRIVACY NOTICE

This Agreement is made between Lilly and the HCO. However, as PAG signatory is providing business contact information please note the privacy statement below.

Your personal information, including your name and business contact details, has been obtained from this contract. It will be used by Lilly, or third parties acting on our behalf, for contacting you in relation to this agreement.

We may also use the information to meet legal or regulatory obligations, inclusive of company record retention. You do not have to share your information with us, but if you choose not to share your information, we will not be able to execute this agreement.

We may share your personal information with third parties to whom the personal information may be disclosed for purposes consistent with those identified in this notice. All third parties that have access to your information have agreed to protect the information and to use it only as directed by us.

We may be required to disclose your information in response to lawful requests by public authorities, including to comply with national security or law enforcement requests. Your information will be saved for a period of time needed to fulfil legitimate and lawful business purposes in accordance with Lilly’s records retention policies and applicable laws and regulations.

We may transmit personal information about you to other Lilly affiliates worldwide. These affiliates may in turn transmit personal information about you to other Lilly affiliates. Some of Lilly’s affiliates may be located in countries that do not ensure an adequate level of data protection. Nevertheless, all of Lilly’s affiliates are required to treat personal information in a manner consistent with this notice. To obtain additional information regarding the basis for transfers and safeguards that Lilly has in place for cross-border

transfers of personal information, please contact us at privacy@lilly.com or visit <https://www.lilly.com/privacy>.

We provide reasonable physical, electronic and procedural safeguards to protect information we process and maintain. For example, we limit access to your information to authorised employees, agents, contractors, vendors, subsidiaries, and business partners, or others who need such access to information to carry out their assigned roles and responsibilities on behalf of Lilly. Although we try to protect the information we process and maintain, no security system can prevent all potential security breaches.

You have the right to request information from us on how your personal information is being used and with whom it is being shared. You also have the right to request to see and get a copy of the personal information that Lilly has about you, request its correction or request it be deleted or request a copy of the Standard Contractual Clauses (SCCs) and Appendix for European Economic Area and Swiss data transferred pursuant to SCCs. These requests should be sent to datarights@lilly.com.

If you wish to raise a complaint on how Lilly has handled your personal information, you can contact Lilly's Data Protection Officer at privacy@lilly.com who will investigate the matter. If you are not satisfied with Lilly's response or believe we are processing your personal information not in accordance with the law you can register a complaint with a Data Protection Authority (DPA).

16. APPLICABLE LAW AND DISPUTES

- 16.1. This Agreement is governed by and construed in accordance with the laws of Denmark.
- 16.2. Any disputes or controversy arising out of or relating to this Agreement shall be submitted solely to the courts of Copenhagen.

This Agreement has been executed in two counterparts, of which the parties have taken one each.

Eli Lilly Danmark A/S

Signature:

Name: Lone Rosenørn Jakobsen

Title: Country Lead

Date:

Colitis-Crohn Foreningen

Signature:

Name: René Skau Björnsson

Title: Sekretariatschef

Date:

23/4-2025



COLITIS-CROHN FORENINGEN
Patientforeningen for tarmsyge

Ansøgning om sponsorat og/eller et Grand

CCF-Foreningen for tarmsyge vil igen i år sætte nationalt fokus på tarmsyge, ikke kun d. 19 maj – der er den officielle Worldwide Awareness Day, men i hele maj måned.

Vi har de sidste år fået nogle gode erfaringer med hvad der virker. Det bygger vi videre på. Så vi fortsætter rejsen med at få udbredt viden – og øge kendskabet til tarmsyge i Danmark.

Vi vil samtidig lave en indsamling på tværs af landet under navnet: #Det rullende budskab, hvor indsamlede penge går til at udbrede og øge viden om tarmsyge.

Derfor tillader vi os, at fremsende denne ansøgning, hvor ethvert bidrag er kærkommen.

Vi har delt Maj måneds awareness projekter op i flere elementer, således I har mulighed for, at vurdere om, der er specifikke områder, der kunne have jeres interesse at støtte op om:

- | | |
|---|------------------|
| 1) National awareness udenfor sundhedssektoren | Pris: 56.800 kr. |
| 2) Pamflet til danske hospitaler i maj måned | Pris: 16.800 kr. |
| 3) Andre materialer i maj måned 2025 til gastro-afdelinger | Pris: 56.500 kr. |
| 4) Worldwide Awareness Day d. 19. maj 2025 | Pris: 79.900 kr. |
| 5) Andre tiltag i forbindelse med, at der i maj bliver sat fokus på tarmsyge: | Pris: 16.000 kr. |
| 6) Opgradering af CCF- Foreningen for tarmsyges "gamle" brochurer. | Pris: 44.200 kr. |

På de efterfølgende sider, kan du/I få mere viden om de individuelle projekter.

Hvad er der i det for jer:

- At I støtter CCF – Foreningen for tarmsyge med at få udbredt viden og kendskab om tarmsygdomme, men hvor der også er en direkte service til tarmsyge, herunder børn og deres pårørende.
- Mulighed for at få vist logo og navn med tak på CCF's officielle facebook side
- Mulighed for at komme med en lille film på ½ minut, hvor I præsenterer jeres sponsorat d. 19. maj.
- Ved sponsorater over 25.000 kr. mulighed, for at komme på scenen og overrække check.

Ellers evt. ring eller mail til Benthe tlf. 20701340 eller mail: benthe@ccf.dk, hvor vi kan tale mere om muligheder eller hvis der er spørgsmål.

Med venlig hilsen

På vegne af CCF – Foreningen for tarmsyge

Vera Slyk Pedetersen og Benthe Bertelsen





1) National awareness udenfor sundhedssektoren:

Pris: 56.800 kr.

Vi havde stor succes med at lave awareness udenfor sundhedssektoren i 2024 og vi kan se, at det har givet en langtidseffekt at række ud til danskerne gennem bl.a. GO-CARDS med et vigtigt budskab, brochure m.m. Vi har aftalt med GO-CARD, at de gentager successen; GO-CARD med et vigtigt budskab, vil køre fra 10 – 22. maj 2025 (er købt og betalt). Forsiden vil stadigvæk være CCF's nye plakat malet af den unge kunstner Bastian Svendsen. På bagsiden vil vi denne gang lave en "call to action" med opfordring til at melde sig ind i CCF.

- a) For, at øge fokus, vil vi om muligt gerne investere i "hoved", der hænger på alle metalholdere, hvor GO-CARD'ene hænger. **Pris: 24.000 kr.**
- b) Mens GO-CARD-kampagnen kører lægges revideret pamflet ud på 545 caféer, restauranter og biografteater. **Pris: 18.000 kr.**
- c) Materialer bl.a. optryk af 6.000 revideret pamflet, ændring af GO-card bagside **Pris: 14.800 kr.**

I alt for oplysning udenfor hospitalerne

Pris: 56.800 kr.

2) Pamflet til på danske hospitaler i maj måned

Pris: 16.800 kr.

Der er stor begejstring for CCF – pamflet, der blev udgivet første gang i 2023. Opgradering og genoptryk (læger og frivillige arbejder pro-bono)

- Revidering og layout 4.800 kr.
- Genoptryk (5000 stk.) 8.500 kr.
- Øversættelse til arabisk 3.500 kr. *1
- Revideret pamflet oversættes til engelsk u.br., og vil blive oversat til færøsk u.br.
- Den reviderede pamflet ligger igen på EFCCA's hjemmeside. Mange har givet udtryk for behov for en arabisk pamflet. Ideen er, at den lægges på CCF's ny hjemmeside til download.

I alt pamflet til på danske hospitaler i maj måned

Pris: 16.800 kr.

3) Andre materialer i maj måned 2025 til gastro-afdelinger

Pris: 56.500 kr.

- a) Genoptryk af de store plakater **2.500 kr.**
(flere afdelinger har efterspurgt disse; underviser efter dem.)
- b) Udvikling, optryk af mindre kort **3.500 kr.**
Forsideplakat, bagside info. om lokalafdelinger rundt om i hele landet
- c) Børne billede "brochure" **19.200 kr.**
m/pædagogiske tegninger til samtale dialog m/ børn (afdelinger efterlyser fysisk materiale til børn. Denne ide er udviklet i samarbejde med børn og forældre på børne- og forældre kursus, samt afprøves på senest børne og forældre kursus
Layout 3.500 kr.
Tryk af 10 sider farverig brochure x 5000 stk. 15.700 kr.
- d) Tarmpas **9.500 kr.**
Flere lande har lavet et term "rejse" pas, til stor glæde for små, unge og ældre medlemmer
Layout ved grafiker så den kan downloades af medlemmer og trykkes 4.500 kr.
Mindre optryk til præmier ved konkurrencer i maj f.eks. mal på ste 5.000 kr.
Senere vil tarmpas kunne købes i WEB-shop, hvis man ikke ønsker at downloade
- e) Forsendelse og omdeling af diverse af ovenstående på gastro-afdelinger **5.000 kr.**

I alt andre materialer i maj måned 2025 til gastro-afdelinger m.fl.

56.500 kr.

4) Worldwide Awareness Day d. 19. maj 2025

Pris: 79.900 kr.





CCF og medlemmer har gennem mange år ønsket at lave en større komsammen d. 19 maj. Målet er at styrke fællesskabet, gøre opmærksom på, at foreningen eksisterer og lave indsamling samtidig. På tværs af lokalafdelinger er det aftalt, at invitere 200 personer og afholde det i Odense. Vi er opmærksomme på at flere i industrien ikke giver sponsorater til underholdning, men det ikke det, der ansøges om her. Vi har allerede anmodet Storebæltsbroen m.fl. om igen i år at lyse broen op i lilla den 19. maj 2025. Det var en stor succes sidste år. Denne gang vil der være gæster tæt på og nogle vil skulle køre på broen retur fra eventet. Grundet vind og vejrforhold, og flere af vores tarmsyge medlemmer har behov for både drikke, lidt at spise, være indendørs og kunne sidde ned, har vi fået aftale med H.C. Andersen Comwell, Odense, som er de billigste, og de har givet en klækkelig rabat oveni:

A) Leje af lokale	30.000 kr.
B) Forplejning (sandwich, 1 sodavand, kaffe og the til 200 personer)	35.400 kr.
C) Teknisk assistance til fx læge eller firma kan holde oplæg på en scenen.	7.500 kr.
Herunder evt. lille film fra sponsorer med deres donation etc.	
D) Kage til kaffen, men er ikke første prioritering	6.000 kr.

I alt worldwide Awareness Day d. 19. maj 2024 i Odense

79.900 kr.

5) Andre ting i forbindelse med, at der i hele maj bliver sat fokus på tarmsyge: 16.000 kr.

- a) Socialmedie kampagne dagligt med 1-2 opslag pr. dag.
Teknisk konsulent assistance til at assistere med udvikling af sociale medie opslag og være behjælpelig med at styre kampagnen, som også samkøres med CCF-Foreningens nye hjemmeside 10.000 kr.
- B) Stort TV til mødelokale på kontoret i Odense
I forbindelse med CCF-Foreningen er flyttet til nye lokaler, kan vi afholde flere møde "in-house" bl.a. unge teamaftner, workshops og undervisning m.fl. 6.000 kr.

I alt andre ting i forbindelse med, at der i hele maj bliver sat fokus på tarmsyge: 16.000 kr.

6) Opgradering af CCF- Foreningen for tarmsyges "gamle" brochurer generelt: 44.200 kr.

CCF har 10 brochurer, som trænger til en kraftig opgradering (informationer er out-dated for flere af dem). Det Lægelige Råd og andre relevante professionelle har tilbudt u.be., at gennemgå dem alle. Ideen er ikke at trykke disse tunge brochurer op i større oplag, men have dem liggende på den nye hjemmeside, som folk så kan downloade. (besparelse og klimavenlig). De skal forbi en "layouter" i byen, som skal gøre alle brochurerne digital-egnede. Samtidig vil CCF- Foreningen lave en A5-folder, indenfor hvert område. Hospitalet har stort behov for at give lidt information om det helt konkrete sygdomsområde f.eks. Crohns, Socialrådgiveren, Mit barn har fået IBD m.fl. Behovet bliver nok ikke mindre i takt med sundhedsreformen ønsker, at flytte store dele af tarmsyge ud til praktiserende læger. Igen er der et hold, der arbejder uden beregning på dette projekt.

- a) Layout og opsætning af brochurer, og gøre dem klar til hjemmesiden, som download: 12.500 kr. *1
- b) Layout og opsætning af A5-foldere m/ henvisning til hjemmeside 6.000 kr. *2
- c) Optryk af A5-foldere ca. 1000 stk. af hver 25.700 kr. *2

*1: Det er et større projekt, men rejser penge hertil, forventes mange af dem færdige inden udgangen af 2025.
*2: Når vi at rejse penge til A5-foldere og trykning af disse, vil de blive delt ud i maj 2025.

I alt opgradering af CCF- Foreningen for tarmsyges ældre brochurer generelt:

44.200 kr.

Alle priser nævnt i punkterne 1 – 5 er eksklusive moms.